Benson CA, Kaplan JE, MasurH, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIVMedicine Association/Infectious Diseases Society of America. Clin Infect Dis.2005;40:S131-S235.
2.
Powderly W.Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. Clin Infect Dis.2000;31:597-601.
3.
Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDSdefining opportunistic illnesses, 1992-1997. MMWR CDC Surveil Summ. 1999;48(SS-2):1-22.
4.
AIDSinfo. 2001US Public Health Service/Infectious Diseases Society of America guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Available at: www.aidsinfo.nih.gov/guidelines. Accessed September 20, 2005.
5.
Hermsen ED, Wynn HE, McNabb J. Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy. Am J Health-Syst Pharm. 2004;61:245-256.
6.
French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615-1627.
7.
Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399-406.
